![]() |
|
|
Vol. 281, Issue 2, 941-949, 1997
Department of Pharmacology (N.G., C.G., A.B.),
University of
Florence, Viale G.B. Morgagni 65, I-50134 Florence and Institute of
Pathology (L.P, S.C., A.Q.), University of Florence, Viale G.B.
Morgagni 50, I-50134 Florence, Italy
Inactivation of the Kv1.1 gene, which codes for a member of the
Shaker-like potassium channels by an antisense
oligodeoxyribonucleotide (aODN), was carried out in mice. The effect of
this inactivation on analgesia induced by morphine (5-9 mg
kg
1 s.c.) and baclofen (2-5 mg kg
1 s.c.)
was investigated in the mouse hot-plate test. Mice received a single
intracerebroventricular injection of mKv1.1 aODN (0.5, 1.0, 2.0 or 3.0 nmol per injection), degenerated ODN or vehicle on days 1, 4 and 7. A
dose-dependent inhibition of morphine and baclofen antinociception was
observed 72 h after the last intracerebroventricular aODN
injection, whereas degenerated ODN and vehicle, used as controls, did
not affect morphine- and baclofen-induced antinociception. Sensitivity
to both analgesic drugs returned to the normal range 7 days after the
end of the aODN treatment, which indicated the absence of any
irreversible damage or toxicity caused by aODN. Quantitative reverse
transcription-polymerase chain reaction analysis demonstrated that a
decrease in mKv1.1 mRNA levels occurred only in the aODN-treated group,
being absent in all control groups. Furthermore, neither aODN,
degenerated ODN nor vehicle produced any behavioral impairment of mice.
These results indicate that the mKv1.1 potassium channel, whose gene
expression we specifically modulated by means of the antisense ODN
strategy, plays an important role in central analgesia induced by
morphine and baclofen.